Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.44 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3283249 | 0.87 | MTNR1A (0.53) | SIGMAR1MTNR1AMTNR1B | |
| SCHEMBL3283908 | 0.86 | SIGMAR1 (0.56) | SIGMAR1MTNR1AMTNR1B | |
| SCHEMBL651178 | 0.83 | MTNR1A (0.60) | SIGMAR1MTNR1AMTNR1BGRM7 | |
| SCHEMBL3291899 | 0.81 | MTNR1A (0.55) | MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL3284594 | 0.77 | MTNR1A (0.52) | MTNR1AMTNR1B | |
| SCHEMBL12667026 | 0.77 | MTNR1A (0.51) | MTNR1AMTNR1B | |
| SCHEMBL3284781 | 0.76 | MTNR1A (0.52) | SIGMAR1MTNR1AMTNR1BGRM7 | |
| SCHEMBL3284773 | 0.76 | MTNR1A (0.52) | SIGMAR1MTNR1AMTNR1BGRM7 | |
| SCHEMBL3284241 | 0.76 | MTNR1A (0.50) | MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL14113226 | 0.75 | MTNR1A (0.59) | SIGMAR1MTNR1AMTNR1BGRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709647-B2 | Tetrahydroquinoline cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | claimed |
| US-7709647-B2 | Tetrahydroquinoline cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20060160850-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | SIGMAR1 104/4885MTNR1A 121/4885MTNR1B 44/4885 |
| US-20060160850-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | SIGMAR1 73/4885MTNR1A 319/4885MTNR1B 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.